1. Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
- Author
-
Teresa Caballero, Avner Reshef, Henriette Farkas, Aharon Kessel, María C Ortega López, Werner Aberer, Moshe Y. Vardi, and James Hao
- Subjects
Pediatrics ,medicine.medical_specialty ,C1 inhibitor deficiency ,Adolescent ,Immunology ,Phases of clinical research ,Bradykinin ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Symptom relief ,Icatibant ,Immunology and Allergy ,Medicine ,Humans ,030212 general & internal medicine ,Letters to the Editor ,Letter to the Editor ,business.industry ,Angioedemas, Hereditary ,medicine.disease ,Treatment Outcome ,030228 respiratory system ,chemistry ,Tolerability ,Pediatrics, Perinatology and Child Health ,Hereditary angioedema ,Age of onset ,business ,Rare disease - Abstract
Hereditary angioedema (HAE) is rare disease characterized by recurrent, unpredictable, and debilitating attacks of subcutaneous/submucosal tissue swelling.1,2 The reported median age of onset of HAE due to C1 inhibitor deficiency/dysfunction (type 1/2; C1-INH-HAE) is 11-12 years.1,3 Treatment options for pediatric patients are limited, owing to low childhood diagnosis rates and low representation in investigative clinical trials.4 We present a multicenter, open-label, single-arm, phase 3 study (NCT01386658) investigating the use of icatibant, a bradykinin B2 receptor antagonist, to treat HAE attacks in pediatric patients with a confirmed diagnosis of C1-INH-HAE.5 In Part 1, patients (aged 2 to
- Published
- 2021